J. Whitten

发表

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Inhibitors of ORAI1 Prevent Cytosolic Calcium-Associated Injury of Human Pancreatic Acinar Cells and Acute Pancreatitis in 3 Mouse Models

J. Roos, K. Stauderman, Wei Huang, 2015, Gastroenterology.

A convenient synthetic access to β, β-difluoro-γ-keto-α-amino acids. Application to the synthesis of a potential inhibitor of kynureninase

E. Huber, J. Mccarthy, P. Bey, 1989 .

A protective role for nitric oxide in the oxidative modification of low density lipoproteins by mouse macrophages

S. Mao, G. Ku, M. T. Yates, 1992, FEBS letters.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Journal of medicinal chemistry.

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

A. Drilon, A. Graber, Y. Lu, 2019, Annals of Oncology.

Characterization of cell selectivity of two novel inhibitors of nitric oxide synthesis.

I. McDonald, J. F. French, B. M. Baron, 1992, European journal of pharmacology.

Halogenation of [2‐(trimethylsilyl)ethoxy]methyl (SEM) protected 2,2′‐Bi‐H‐imidazole

D. Matthews, J. Whitten, R. MccarthyJames, 1987 .

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Molecular and Cellular Biochemistry.

Conformationally restricted analogues of nicotine and anabasine.

T. Rao, F. Menzaghi, N. Cosford, 1998, Bioorganic & medicinal chemistry letters.

(R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex.

H. White, I. McDonald, B. M. Baron, 1990, Journal of medicinal chemistry.

Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists.

E. D. De Souza, D. Grigoriadis, T. Webb, 1996, Journal of medicinal chemistry.

A facile synthesis of aromatic trifluoromethyl compounds via orthothio esters

D. Matthews, J. Mccarthy, J. Whitten, 1986 .

Diphenyl 2-pyridylphosphine and di-tert-butylazodicarboxylate:Convenient reagents for the Mitsunobu reaction

M. Kiankarimi, J. Mccarthy, R. Lowe, 1999 .

NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations.

J. Kehne, B. Harrison, M. Palfreyman, 1991, European journal of pharmacology.

Competitive NMDA receptor antagonists; (R)-4-Oxo-5-phosphononorvaline structure-activity relationships

I. McDonald, B. M. Baron, J. Whitten, 1993 .

Synthesis of 3()-phosphonoacetyl-2()-piperidinecarboxylic acid, a conformationally-restricted glutamate antagonist

I. McDonald, R. Cube, B. M. Baron, 1991 .

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

Amy Lin, D. V. Von Hoff, Adam Siddiqui-Jain, 2009, Cancer research.

Total synthesis of psorospermin

M. Schwaebe, J. Whitten, Moran Terence Jarold, 2005 .

Facile Synthesis of the Four 3‐Aminocyclopentane‐1,2‐diol Stereoisomers.

J. Mccarthy, J. Whitten, M. Whalon, 1986 .

(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.

P. Adams, K. Stauderman, T. Rao, 1996, Journal of medicinal chemistry.

A convenient procedure for the preparation of 4(5)-cyanoimidazoles

D. Matthews, J. Mccarthy, J. Whitten, 1986 .

[2-(Trimethylsilyl)ethoxy]methyl (SEM) as a novel and effective imidazole and fused aromatic imidazole protecting group

D. Matthews, J. Whitten, R. MccarthyJames, 1986 .

Determination of the importance of the stereochemistry of psorospermin in topoisomerase II–induced alkylation of DNA and in vitro and in vivo biological activity

L. Hurley, T. Dexheimer, H. Vankayalapati, 2005, Molecular Cancer Therapeutics.

Synthesis and cardiotonic activity of novel biimidazoles.

D. Matthews, J. Mccarthy, J. Whitten, 1990, Journal of medicinal chemistry.

Competitive NMDA receptor antagonists: synthesis of β-ketophosphonate-substituted piperidine carboxylic acid derivatives

I. McDonald, R. Cube, B. M. Baron, 1993 .

Cyanogen Bromide-Dimethylaminopyridine (CAP): A Convenient Source of Positive Cyanide for the Synthesis of 2-Cyanoimidazoles

D. Matthews, J. Mccarthy, J. Whitten, 1988 .

N-cyano-N′-alkylimidazolium ylids as novel intermediates to 2-cyanoimidazoles

D. Matthews, J. Mccarthy, J. Whitten, 1985 .

A one step synthesis of 4‐substituted imidazoles. An important observation when N‐alkylating imidazoles

R. Barbuch, D. Matthews, J. Mccarthy, 1988 .

A One-Step Synthesis of 4-Substituted Imidazoles (III). An Important Observation When N-Alkylating Imidazoles (I).

R. Barbuch, D. Matthews, J. Whitten, 1989 .

A convenient synthetic route to 2,2'-biimidazole

D. Matthews, J. Whitten, R. MccarthyJames, 1986 .

Facile synthesis of the four 3-aminocyclopentane-1,2-diol stereoisomers

J. Mccarthy, J. Whitten, M. Whalon, 1985 .

Stereospecific syntheses of the four diastereomeric 2-amino-5-phenoxycyclopentanols

P. Wiedeman, J. Huffman, R. Barbuch, 1985 .

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

A. Drilon, A. Shaw, S. Ou, 2018, Cancer discovery.

Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.

E. D. De Souza, D. Grigoriadis, T. Webb, 1996, Journal of medicinal chemistry.

Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.

D. Grigoriadis, T. Webb, Chen Chen, 2004, Bioorganic & medicinal chemistry letters.

Nitric oxide synthesis in the CNS endothelium and macrophages differs in its sensitivity to inhibition by arginine analogues.

H. Cheng, I. McDonald, B. M. Baron, 1991, Life sciences.

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Adam Siddiqui-Jain, J. Bliesath, Diwata Macalino, 2012, ACS medicinal chemistry letters.

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

A. Drilon, A. Graber, A. Shaw, 2019, Clinical Research (Excluding Clinical Trials).

A Facile Synthesis of Aromatic Trifluoromethyl Compounds via Orthothio Esters.

D. Matthews, J. Mccarthy, J. Whitten, 1987 .

Rapid microscale synthesis: Solution phase parallel synthesis of a library of piperazines and piperidines using a water soluble base

J. Mccarthy, J. Whitten, Y. Xie, 1998 .

1-(Thienylalkyl)imidazole-2(3H)-thiones as potent competitive inhibitors of dopamine beta-hydroxylase.

R J Broersma, H J Weintraub, D A Demeter, 1990, Journal of medicinal chemistry.

Synthesis of polymer-bound hemoglobin samples

H. Taegtmeyer, J. Baldwin, J. Whitten, 1981 .

Overview: Inhibition of Nitric Oxide Biosynthesis

I. McDonald, J. Whitten, 1992 .

Quarfloxin (CX-3543) disrupts the Nucleolin/ rDNA quadruplex complexes, inhibits the elongation by RNA Polymerase I and exhibits potent antitumor activity in models of cancer

S. O'Brien, W. Rice, D. Drygin, 2008 .

Nickel(0)-catalyzed coupling of vinylzirconiums to α-bromo-α,α-difluoro esters. Convenient generation of a functionalized allyldifluoro moiety

M. Schwaebe, J. Mccarthy, J. Whitten, 2000 .

CM3457, a potent and selective oral CRAC channel inhibitor, suppresses T and mast cell function and is efficacious in rat models of arthritis and asthma (72.3)

J. Roos, K. Stauderman, S. Ramos, 2012, Journal of Immunology.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1 Receptor Antagonists

C. Chen, D. Grigoriadis, T. Webb, 1997 .